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Objective: The goal of this study was to analyze the role of aryl hydrocarbon receptor in
peripheral blood CCR6+CD4+ and CD4+CD25+T cells of patients with rheumatoid arthritis.
Methods: Flow cytometry was applied to determine the proportion of AhR positive cells in
CCR6+CD4+T, CD4+CD25+T and peripheral blood peripheral mononuclear cells from each
subject. AhR mRNA and CYP1A1 mRNA relative expression levels were tested by real-time
PCR.
Results: The percentage of AhR positive cells in peripheral blood mononuclear cells was
higher in RA group than that in healthy cases [(35.23 ± 10.71)% vs. (18.83 ± 7.32)%, p < 0.01].
The expression levels of AhR and CYP1A1 were both increased in patients with RA while
compared to controls [(3.71 ± 1.63) vs. (2.00 ± 1.27), p = 0.002; (2.62 ± 2.08) vs. (0.62 ± 0.29),
p  < 0.01, respectively]. In RA patients, the percentage of AhR positive cells in CD4+CD25+T
cells was signiﬁcantly lower than that from controls [17.90 (6.10 ± 80.10)% vs. (52.49 ± 19.18)%,
p  < 0.01]; In healthy controls, the percentage of AhR positive cells in CD4+CD25+T cells was
signiﬁcantly higher than that in CCR6+CD4+T cells, and was also signiﬁcantly higher than
that  in PBMCs [(52.49 ± 19.18)% vs. (23.18 ± 5.62)% vs. (18.06 ± 7.80)%, X2 = 24.03, p < 0.01]; in
RA  patients, the percentage of AhR positive cells in CCR6+CD4+T cells was signiﬁcantly
increased than that in CD4+CD25+T cells and PBMCs [(46.02 ± 14.68)% vs. 17.90 (6.10 ± 80.10)%
vs. (34.22 ± 10.33)%, X2 = 38.29, p < 0.01]; Nevertheless, no statistically signiﬁcant relationship
was found between clinical data and AhR positive cells in CCR6+CD4+T and CD4+CD25+T
cells.
Conclusion: AhR may participate in the pathological progress of RA by controlling the differ-Please cite this article in press as: Cheng L, et al. Unbalanced expression of aryl hydrocarbon receptor in peripheral blood CCR6+CD4+ and
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.002
entiation of Th17 and Treg cells in peripheral blood.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
 Study originated at Department of Rheumatology and Immunology, The Second Afﬁliated Hospital, Anhui Medical University, Hefei,
hina.
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Expressão  não  equilibrada  do  receptor  de  hidrocarboneto  arílico  nos
linfócitos  T  CCR6+  CD4+  e  CD4+  CD25+  do  sangue  periférico  na  artrite
reumatoide
Palavras-chave:
Artrite reumatoide
Receptores de hidrocarboneto
arílico
Linfócitos T CD4+ CD25+
Linfócitos T CCR6+ CD4+
r  e  s  u  m  o
Objetivo: Analisar o papel do receptor de hidrocarboneto arílico (AhR) nos linfócitos T CCR6+
CD4+ e CD4+ CD25+ no sangue periférico de pacientes com artrite reumatoide (AR).
Métodos: Foi aplicada citometria de ﬂuxo para determinar a proporc¸ão de células AhR posi-
tivas em linfócitos CCR6+ CD4+ e CD4+ CD25+ do sangue periférico e células mononucleares
periféricas de cada indivíduo. Os níveis de expressão relativa de ácido ribonucleico men-
sageiro (do inglês ribonucleic acid, RNAm,) de AhR e RNAm de enzima de primeiro estágio
essencial para o AhR (CYP1A1) foram testados por reac¸ão em cadeia de polimerase (do inglês
polymerase chain reaction, PCR,) em tempo real.
Resultados: A percentagem de células AhR positivas nas células mononucleares do sangue
periférico foi maior no grupo com AR do que nos indivíduos saudáveis [(35,23 ± 10,71)% vs.
(18,83  ± 7,32)%, (p < 0,01)]. Os níveis de expressão de AhR e CYP1A1 estavam aumentados
em  pacientes com AR quando comparados com os controles [(3,71 ± 1,63) vs. (2,00 ± 1,27),
p  = 0,002; (2,62 ± 2,08) vs. (0,62 ± 0,29), p < 0,01, respectivamente]. Em pacientes com AR, a
percentagem de células AhR positivas nos linfócitos T CD4+ CD25+ foi signiﬁcativamente
inferior à dos controles [17,90 (6,10 ± 80,10)]% vs. (52,49 ± 19,18)%, p < 0,01]; em controles
saudáveis, a percentagem de células AhR positivas nos linfócitos T CD4+ CD25+ foi signiﬁca-
tivamente mais elevada do que nos linfócitos T CCR6+ CD4+ e também foi signiﬁcativamente
maior do que nas células mononucleares do sangue periférico (do inglês peripheral blood
mononuclear cells, PBMC,) [(52,49 ± 19,18)% vs. (23,18 ± 5,62)% vs. (18,06 ± 7,80)%, X2 = 24,03,
p  < 0,01]; em pacientes com AR, a percentagem de células AHR positivas nos linfócitos T
CCR6+ CD4+ era signiﬁcativamente maior em comparac¸ão com os linfócitos T CD4+ CD25+
e  PBMC (46,02 ± 14,68)% vs. [17,90 (6,10 ± 80.10)]% vs. (34,22 ± 10,33)%, X 2 = 38,29, p < 0,01]; no
entanto, não foi encontrada correlac¸ão estatisticamente signiﬁcativa entre os dados clínicos
e  células AhR positivas em linfócitos T CCR6+ CD4+ e CD4+ CD25+.
Conclusão: O Ahr pode participar do progresso patológico da AR ao controlar a diferenciac¸ão
de  linfócitos Th17 e Treg no sangue periférico.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC
BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Rheumatoid arthritis (RA) is a systemic chronic inﬂam-
matory disease that affects about 1% of the population.1
The aryl hydrocarbon receptor (AhR), consisted of 806
amino acids, is a transcription factor that belongs to the
bHLH (basic Helix-Loop-Helix)-PAS (Per-ARNT-Sim) family.2
AhR combines with chaperone proteins in the cytoplasm
and maintains an inactive form in the absence of its lig-
ands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and
6-formylindolo[3,2-b]carbazole (FICZ). Once activated, AhR
dissociates from the proteins and transfers to the nucleus to
induce the expression of downstream genes.
T helper (Th) 17 cells and regulatory T cells (Treg) are groups
of the CD4+T cells family. Interleukin (IL) 17 – producing Th17
cells predominantly express CC chemokine receptor (CCR)
6 which is a crucial marker for Th17 cells in autoimmunePlease cite this article in press as: Cheng L, et al. Unbalanced expressio
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http:/
diseases3; previous study has suggested that rheumatoid
arthritis in animal models could be improved when treated
with anti-CCR6 mono clonal antibody,3 which may indicateCCR6 expression plays a primary role in autoimmune diseases.
CCR6+CD4+T cell is the main component of Th17 cells,3–6 and
meanwhile CCR6 is regarded as a biomarker of human Th17
cells.5,6 The CD4+CD25+ lineage of Treg is an immunosup-
pressive cell which plays a vital character in immune and
autoimmune responses and the transcription factor forkhead
box protein P3 (Foxp3) has been thought to determine the Treg
cells lineage.7 Recently, studies have found AhR was highly
expressed in Th17 and Treg cells,8,9 which could activate its
signaling pathways, control the differentiation of the cells, and
further involve in the pathogenesis of autoimmune diseases
in a ligand-speciﬁc manner.8,10,11
Although AhR seen as a major participant in autoimmune
diseases has been studied and identiﬁed in prior researches,
how exactly AhR linked to rheumatoid arthritis in human
beings is poorly understood. In the present study, we  inves-
tigate the mRNA  expression levels of AhR and CYP1A1 in
peripheral blood mono-nuclear cells (PBMCs) and the propor-n of aryl hydrocarbon receptor in peripheral blood CCR6+CD4+ and
/dx.doi.org/10.1016/j.rbre.2016.07.002
tion of AhR positive cells in CCR6+CD4+ and CD4+CD25+T cells
to study the role of AhR in CCR6+CD4+ and CD4+CD25+T cells
from RA patients.
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Table 1 – Primers used for the quantitative real-time
RT-PCR.
Genes Primer
AhR
Forward primer 5′-ATACCGAAGACCGAGCTGAAT-3′
Reverse primer 5′-CCAGCAGACACCTTAGACGAC-3′
ˇ-Action
Forward primer 5′-AGCGAGCATCCCCCAAAGTT-3′
Reverse primer 5′-GGGCACGAAGGCTCATCATT-3′
CYP1A1r  e v b r a s r e u m a t o l
atients  and  methods
tudy  subjects
hirty-ﬁve patients with RA (mean age 49.22 ± 8.94, 8 males
nd 27 females) according to the 1987 revised criteria of
merican Rheumatism Association12 were recruited from the
epartment of Rheumatology, The Second Afﬁliated Hospi-
al of Anhui Medical University. The inclusion criteria of the
tudy (a) a deﬁnite diagnosis, (b) free of other autoimmune
iseases, (c) undergoing no infectious diseases, (d) treatment
ith same drugs for RA patients. Meanwhile, fourteen age and
ex matched healthy controls were randomly selected from
ealth center (mean age 46.5 ± 7.5, 3 males and 11 females).
he clinical parameters and the disease activity score in 28
oints (DAS28) were calculated in detail. The Ethics Commit-
ee of the Hospital approved the study. Informed consent
as obtained from the patients or from their relatives if the
atients were incapable of consent.
ell  isolation
-mL venous peripheral blood was stored in anticoagula-
ion tube containing EDTA as the anticoagulant. PBMCs were
eparated using density-gradient centrifugation (Beijing Solar-
io Science and Technology Company, Beijing, China). Total
BMCs number of each sample was not less than 1 × 106.
low  cytometry
ell  surface  markers
 L CD25-PE and 2 L CD4-PerCP-Cy5.5 were both added to
he marked ﬂow tubes (a, b), at the same time 5 L CCR6-PE
nd 2 L CD4-PerCP-Cy5.5 were added to the other two tubes
c, d). After the liquid in four tubes was mixed, we placed them
n a refrigerator at 4 ◦C for 20 min. Then 2-mL buffer was pre-
ared to wash them for once. The above-mentioned antibodies
ere purchased from Becton, Dickinson and Company (BD) of
merican.
ixation  and  perforation
00-L PBMCs was mixed with 500 L ﬁxatives (Becton, Dickin-
on and Company, American) in four tubes to give incubation
voiding light at 4 ◦C temperature and after that, 1-mL buffer
as to wash them for two times.
he  indirect  method  of  marking  AhR
ach tube was added the mixture of 2 L ﬁrst antibody (the
ntibody of anti-aryl hydrocarbon receptor, Abcam Company,
ngland) and 2 L phosphate buffered saline (PBS). 1-mL buffer
as applied to wash them after put the mixture at room tem-
erature to avoid light for 1 h and then 2 L second antibody
mouse monoclonal (2A9) secondary antibody to rabbit IgG
eavy chain (FITC), Abcam Company, England) was added toPlease cite this article in press as: Cheng L, et al. Unbalanced expressio
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http:/
he four tubes and placed them in chamber at room temper-
ture to avoid light for half an hour. 2 L buffer was used to
ash them for two times and at last 200 L PBS was added to
he tubes.Forward primer 5′-CATCCCCCACAGCACAACAAGAGA-3′
Reverse primer 5′-GCAGCAGGATAGCCAGGAAGAGAA-3′
Flow-cytometric  analysis
The percentage of CD4+CD25+ and CCR6+CD4+ T cells in
PBMCs and the proportion of AhR positive cells in PBMCs,
CD4+CD25+T and CCR6+CD4+T cells were all detected by Cel-
lQuest software (FACSaclibur, BD Company). The number of
cells was tested at least 100,000 at a time and FlowJo7.6.1 was
applied to analyze the data.
Isolation  and  reverse  transcription  of  total  RNA
Total RNA from RA peripheral blood mononuclear cells was
separated using Trizol reagent (Invitrogen, California, USA).
Primers were designed and synthesized by Takara Biotechnol-
ogy (Tokyo, Japan). The speciﬁc primer sequences were shown
in Table 1. The PrimeScript RT reagent Kit (Takara Biotech-
nology, Japan) was used to perform the synthesis of cDNA
according to the manufacturer’s instructions.
Real-time  quantitative  PCR
The PCR was performed in a 20 L reaction system contain-
ing 1.6 L primers (0.8 L forward primer and reverse primer,
respectively), 2 L cDNA, 0.4 L ROX Reference dye II, 6 L
dH2O, and 10 L SYBR Premix Ex TaqTM II. All the samples were
ampliﬁed at the same site on ABI 7500 real-time polymerase
chain reaction system (Applied Biosystems, Foster City, CA).
2−ct was used to compute the expression value of AhR and
CYP1A1.
Laboratory  measurement
For all the RA patients, erythrocyte sedimentation rate (ESR),
C reactive protein (CRP) and anti-cyclic citrullinated peptide
antibody (A-CCP) were measured.
Statistical  analysis
Statistical analysis was carried out by the Statistical Package
for Social Sciences 10.0 software e (SPSS Inc.; 2000). Quantita-
tive variables were recorded by mean ± SD,  and the differences
were analyzed using t test if the data meet the normaln of aryl hydrocarbon receptor in peripheral blood CCR6+CD4+ and
/dx.doi.org/10.1016/j.rbre.2016.07.002
distribution and homogeneity of variance. However, nonpara-
metric distribution data were described by median value and
interquartile range (IQR). ANOVA was used to compare the
data in three groups, and the comparison between two groups
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Fig. 1 – The percentage of AHR in peripheral blood
response to its self-antigen. The self-tolerance in RA patientsmononuclear cells from RA patients and healthy controls.
in the three groups was analyzed by LSD-t or Mann–Whitney U
test. Spearman correlation analysis was applied in our study.
p < 0.05 was thought to be statistically signiﬁcant.
Results
The  percentages  of  AhR  in  PBMCs  from  patients  with  RA
and controls
As shown in Fig. 1, the percentage of AhR positive cells was
decreased in healthy controls (18.83 ± 7.32)% than that in
patients with RA (35.23 ± 10.71)% (p < 0.01).
The  increased  mRNA  levels  of  AhR  and  CYP1A1  in  PBMCs
from RA  patients
As shown in Fig. 2, AhR and CYP1A1 mRNA  expression levels
were both increased in patients with RA when compared with
controls [(3.71 ± 1.63) vs. (2.00 ± 1.27), p = 0.002; (2.62 ± 2.08) vs.
(0.62 ± 0.29), p < 0.01, respectively].
The  percentage  of  AhR  in  CCR6+CD4+T  and  CD4+CD25+T
cells from  RA  cases  and  healthy  subjectsPlease cite this article in press as: Cheng L, et al. Unbalanced expressio
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http:/
As shown in Fig. 3, the percentage of AhR positive
cells in CCR6+CD4+T cells was clearly higher in patients
(46.02 ± 14.68)% than that in healthy subjects (23.18 ± 5.62)%
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Fig. 2 – Expression levels of AHR and CYP1A1 mRNA  in p 1 6;x  x x(x x):xxx–xxx
(p < 0.01) (Fig. 3A). In contrast, the percentage of AhR positive
cells in CD4+CD25+T cells was decreased in RA patients [17.90
(6.10, 80.10)]% than healthy group (52.49 ± 19.18)% (Fig. 3B). Sig-
niﬁcant differences were existed between two groups (p < 0.01).
The  comparison  about  the  percentage  of  AhR  positive  cells
in peripheral  blood  CD4+CD25+T,  CCR6+CD4+T  cells  and
PBMCs  from  Normal  control  and  RA  group
In the healthy group, the percentage of AhR positive cells
in CD4+CD25+T cells was signiﬁcantly higher than that in
CCR6+CD4+Tcells, and was also statistically higher than in
PBMCs [(52.49 ± 19.18)% vs. (23.18 ± 5.62)% vs. (18.06 ± 7.80)%,
X2 = 24.03, p < 0.01] (Fig. 4A). Nevertheless, the percentage
of AhR positive cells in CCR6+CD4+T cells was signiﬁcantly
increased than that in CD4+CD25+T cells, and was also sig-
niﬁcantly higher than that in PBMCs [(46.02 ± 14.68)% vs.
17.90 (6.10, 80.10)% vs. (34.22 ± 10.33)%, X2 = 38.29, p < 0.01]
(Fig. 4B).
Correlation  between  the  AhR  positive  cells  in  peripheral
blood CCR6+CD4+T,  CD4+CD25+T  cells  and  major  clinical
parameters  from  RA  patients
We conducted Spearman’s correlation to assess the association
between AhR/CYP1A1 mRNA expression levels, AhR positive
cells in peripheral blood CCR6+CD4+T, CD4+CD25+T cells and
major clinical parameters. However, no signiﬁcant correlation
was found between them, and the details were summarized
in Table 2.
Discussion
RA is a systemic autoimmune disease primarily manifest as
polyarthritis, especially the small joints of hands and feet, that
is characterized by joint destruction and chronic disability.13
However, the mechanisms about the immune pathways in RA
have not been identiﬁed yet. For the past few years, a wealthy
of data has showed self-tolerance plays a dominant role in
autoimmunity including RA as it erroneously was activated inn of aryl hydrocarbon receptor in peripheral blood CCR6+CD4+ and
/dx.doi.org/10.1016/j.rbre.2016.07.002
may be regulated by various factors such as cytokine, environ-
mental risks and lifestyle factors.14 Currently, it was believed
that aberrant T-cell homeostasis plays a great part in the
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Fig. 3 – The percentages of AHR positive cells in CCR6+CD4+T (A) and CD4+CD25+T (B) cells from healthy controls and RA
patients.
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athogenesis. Moreover, Treg cells dysfunction and/or Th17
ells dysregulation are thought to contribute to the devel-
pment of autoimmune disorders. Similarly, accumulated
vidence indicates AhR plays a critical place in regulating
he differentiation of Th17 and Treg cells, affecting the
evelopment of a number of autoimmune diseases includingPlease cite this article in press as: Cheng L, et al. Unbalanced expressio
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http:/
A.11,15–20
AhR is located in the cytoplasm and maintains an inactive
orm in the absence of its ligands such as TCDD and FICZ. Once
Table 2 – The correlation between percentages of AhR positive c
AhR/CYP1A1mRNA expression from RA patients and clinical pa
Clinical parameters ESR CRP 
AhR mRNA
r-Value 0.115 0.014 
p-Value 0.511 0.936 
CYP1A1 mRNA
r-Value 0.007 0.149 
p-Value 0.967 0.392 
CCR6+CD4+T
r-Value −0.262 −0.273 
p-Value 0.14 0.124 
CD4+CD25+T
r-Value −0.129 0.013 
p-Value 0.475 0.943 activated, AhR complex combines with AhR nuclear transloca-
tor protein (Arnt) to be heterodimer in the nucleus where they
bind to speciﬁc DNA sequences known as xenobiotic-response
elements (XRE), and this binding will produce some reaction.
During this activated process, a vital phase I enzyme of AhR
(CYP1A1) that is a most widely studied responsive gene had an of aryl hydrocarbon receptor in peripheral blood CCR6+CD4+ and
/dx.doi.org/10.1016/j.rbre.2016.07.002
higher expression.21 Several groups previously have shown a
state AhR was highly expressed in ubiquitous cells including
Th17, Treg, dendritic cells (DCs).8,9,22
ells in CCR6+CD4+T/CD4+CD25+T cells,
rameters.
Anti-CCP DAS28 scores Course
0.003 0.068 −0.107
0.987 0.698 0.541
−0.035 0.143 0.031
0.842 0.411 0.860
0.055 −0.187 −0.309
0.761 0.296 0.08
0.140 −0.045 −0.081
0.436 0.804 0.653
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Interestingly, the essential factor of the pathogenesis
on traditional view in autoimmune diseases is mainly due
to Th1 and Th2 cells ratio imbalance. However, recent
researchers had a tendency to focus more  on the bal-
ance between Th17 and Treg cells belong to the family of
CD4+T cells. Quintana et al.17 showed that AhR activation by
its ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin induced func-
tional Treg cells that suppressed experimental autoimmune
encephalomyelitis (EAE), but boosted Th17 cells differentia-
tion and furthermore increased the risk of EAE if the ligand
was FICZ in animal models. This study further illuminated
the importance of the balance on Th17 and Treg cells. A study
by de Kleer et al.23 showed a signiﬁcantly higher number of
CD4+CD25+Treg cells was found in juvenile idiopathic arthri-
tis (JIA) than that in extended oligoarticular JIA (ext-OA JIA),
and suggested the higher frequencies of CD4+CD25+Treg cells
in synovial tissue of patients with JIA, the lower severity of
the disease. It has been reported CD4+CD25+Treg-deﬁciency
might exacerbate symptoms in patients with RA.24,25 In
the meantime, Nguyen et al.26 showed the disease progres-
sion could not be prevented by CD4+CD25+Treg cells, but
the severity would be lowered for its immunosuppressive
function.
To date, the study about AhR in peripheral blood as well
as in Th17 and Treg of RA patients is much less. Based on
the mentioned studies and the notion, we conducted the
experiment. Consistent with previous ﬁndings,8,10,11,17 ﬁrstly,
we found a statistically higher frequency of AhR positive
cells in RA patients when compared with healthy controls.
In addition, we  also got AhR and CYP1A1 mRNA  were both
overexpressed in patients with RA. Given the result, we might
speculate AhR was activated and played a signiﬁcant role in
RA patients. Secondly, our study showed not only the percent-
age of AhR in CCR6+CD4+T cells was enriched but also the
percentage in CD4+CD25+T cells was reduced in RA patients
compared to healthy subjects. Moreover, in present study, the
highest frequency of AhR positive cells in CD4+CD25+T was
tested of CCR6+CD4+T and PBMCs in healthy persons, how-
ever its proportion in CCR6+CD4+T cells was increased than
PBMCs and both of them were higher than in CD4+CD25+T
cells. All these ﬁndings collectively supported the view that
AhR plays an essential role in differentiation and function
of CD4+CD25+Treg and CCR6+CD4+Th17, controlling the bal-
ance of Th17 and Treg cells, and what could provide more
therapeutic approaches in RA. However, no signiﬁcant cor-
relations between AhR/CYP1A1 mRNA  expression levels, the
AhR positive cells in CD4+CD25+T as well as CCR6+CD4+T
cells and CRP, ESR, A-CCP, DAS28, course of disease were
found. It potentially told us they could not reﬂect the dis-
ease activity or insufﬁcient sample size might be one of the
reasons.
In conclusion, our ﬁndings ﬁrst demonstrate an associa-
tion between AhR and CD4+CD25+Treg, CCR6+CD4+Th17 cells
in peripheral blood from RA patients, which may broaden our
horizons in the etiology of RA and provide new insights into
the pathogenesis of RA. Our results suggest that AhR may playPlease cite this article in press as: Cheng L, et al. Unbalanced expressio
CD4+CD25+T cells of rheumatoid arthritis. Rev Bras Reumatol. 2016. http:/
a central role in controlling the balance of Th17 and Treg for its
unbalanced expression in peripheral blood and further partic-
ipate in the pathogenesis of RA. Of course, these results may
be needed to elucidate in a further research.
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